Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574253 | 0.92 | EPHX2 (0.54) | EPHX2PPARGPPARAPOLBACACB | |
| SCHEMBL15262272 | 0.87 | EPHX2 (0.50) | EPHX2PPARGPPARAPOLBACACB | |
| SCHEMBL9493601 | 0.86 | MMP8 (0.49) | EPHX2PPARGPPARAACACBMMP8 | |
| SCHEMBL5753349 | 0.86 | EPHX2 (0.54) | EPHX2PPARGPPARAPOLBACACB | |
| SCHEMBL27986121 | 0.84 | EPHX2 (0.52) | EPHX2PPARGPPARAPOLBACACB | |
| SCHEMBL1312803 | 0.83 | MMP8 (0.62) | EPHX2PPARGMMP8LDHA | |
| SCHEMBL3091926 | 0.82 | LDHA (0.61) | EPHX2PPARGPPARAACACBEPHX1 | |
| SCHEMBL27686858 | 0.81 | PPARG (0.57) | EPHX2PPARGPPARAPOLBMMP8 | |
| SCHEMBL490486 | 0.81 | LDHA (0.69) | EPHX2PPARGPPARAMMP8LDHA | |
| SCHEMBL6718052 | 0.80 | PPARA (0.51) | EPHX2PPARGPPARAPOLBACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| CN-104245698-A | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL | 2014-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | EPHX2 1190/4885PPARG 1437/4885PPARA 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.